A study published in the New England Journal of Medicine found that the alpha-emitting isotope radium-223 was linked to significantly improved survival in prostate cancer patients. The Phase III study involved 921 men with castration-resistant prostate cancer and bone metastases who did not previously undergo docetaxel therapy. The trial was stopped early after an interim analysis showed that treatment with radium-223 significantly improved survival, resulting in a median overall survival of 14.9 months among patients treated with radium-223 compared with 11.3 months for the placebo group.

Related Summaries